tiprankstipranks
Advertisement
Advertisement

FATE Stock Latest News

Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
RatingsMaintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
1M ago
FATE
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
PremiumThe Fly
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
1M ago
FATE
Fate Therapeutics presents updated Phase 1 data of FT819
PremiumThe Fly
Fate Therapeutics presents updated Phase 1 data of FT819
4M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
PremiumCompany Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
4M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
PremiumCompany Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
4M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
PremiumRatingsFate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
5M ago
FATE
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
Premium
The Fly
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
5M ago
FATE
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
5M ago
FATE
Is FATE a Buy, Before Earnings?
PremiumPre-Earnings
Is FATE a Buy, Before Earnings?
5M ago
FATE
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
PremiumCompany Announcements
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
5M ago
FATE
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
PremiumCompany Announcements
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
5M ago
FATE
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
5M ago
FATE
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
PremiumThe FlyWedbush upgrades Fate Therapeutics to Outperform, raises target to $7
5M ago
FATE
Fate Therapeutics Reports Promising Phase 1 Trial Results
Premium
Company Announcements
Fate Therapeutics Reports Promising Phase 1 Trial Results
5M ago
8K
FATE
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
Premium
The Fly
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
5M ago
FATE
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
PremiumRatings
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
5M ago
FATE
Fate Therapeutics Appoints New CFO Kamal Adawi
PremiumCompany Announcements
Fate Therapeutics Appoints New CFO Kamal Adawi
6M ago
8K
FATE
Fate Therapeutics appoints Adawi as CFO
PremiumThe Fly
Fate Therapeutics appoints Adawi as CFO
6M ago
FATE
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
PremiumCompany Announcements
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
8M ago
FATE
Fate Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsFate Therapeutics Reports Q2 2025 Financial Results
8M ago
FATE
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
Premium
The Fly
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
8M ago
FATE
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
Premium
Ratings
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
8M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >